DNDi began its activities in South Asia in 2004, aiming to build and strengthen regional partnerships for research and development (R&D) on neglected diseases. In India, DNDi supports the government’s goal of eliminating visceral leishmaniasis, which is endemic to parts of the country. This is achieved through clinical trials, capacity-building initiatives, and support for last-mile elimination efforts. DNDi has also established two centers of excellence for managing complicated cases of kala azar.
Additionally, DNDi has implemented visceral leishmaniasis projects in Bangladesh and Nepal. More recently, the DNDi South Asia office has expanded its focus to developing new tools in the fight against lymphatic filariasis, dengue, and mycetoma.
Projects
- Dengue
- Lead Optimization Consortium in India (LOCI)
- LXE408 Novartis
- New treatments for PKDL
- New treatments for HIV/VL
- New VL treatments (South Asia)
English
2019
DNDi South Asia
PHD House, 3rd Floor
4/2 Siri Institutional Area
New Delhi 110016
India
Tel: +91 11 4550 1795
Highlights
2024
Read highlights from our teams and partners in South Asia:
2018
- Supported the Indian National Kala-azar Elimination Programme in building capacity to diagnose kala-azar (visceral leishmaniasis) and post-kala-azar dermal leishmaniasis (PKDL), and by gathering evidence needed to respond to threats to the sustainable elimination of visceral leishmaniasis in the region.
- Completed recruitment for a clinical trial for PKDL, testing amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected by mid-2020.
- Partnered in an MSF study on kala-azar-HIV co-infection in Bihar state to evaluate treatments with amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected in 2019 that will provide key evidence to national and regional decision-makers on the best treatment for co-infected patients.
- Launched GARDP’s 11-country observational study to collect clinical information on treatment of babies with sepsis, to guide the development of new and improved antibiotic treatments for newborns.
